[15] In 2014 Fosun Pharma was part of a consortium to acquire US-listed Chindex International, which owned private hospitals in mainland China.

[16][17] In 2016, according to the Financial Times, Fosun Pharmaceutical made the largest Indian corporate takeover by a Chinese company.

[23][24] In January 2021, the company entered into a partnership with Insilico Medicine, to facilitate the latter's entry into the Chinese market.

[29] Also, BioNTech announced a collaboration with Pfizer to scale-up manufacturing capacity to provide worldwide supply in response to the pandemic.

Fosun's Chief Medical Officer Hui Aimin said that he didn't regret testing BNT162b1 without waiting for all the data.

"[33] Regulation and Commercialization Fosun said it would instead focus on seeking Chinese regulatory approval for BioNTech's other candidate BNT162b2 which was already in Phase III trials by Pfizer since July.

Fosun would apply for a bridge study on BNT162b2, designed to test if the large trial data done overseas could be extrapolated to the populace of China.

[33] In early August, Fosun and BioNTech signed an agreement with HKSE-listed Jacobson Pharma to supply 10 million doses of BNT162b2 to Hong Kong and Macau.